Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Evaluate the safety and tolerability of pegcrisantaspase in combination with venetoclax
(Ven-PegC) and estimate the maximum tolerated doses and/or biologically active doses of
Ven-PegC in patients with relapsed or refractory acute myeloid leukemia (R/R AML)